A2 is dedicated to pushing the boundaries of science to transform medicine and turn the tide on cancer. We are focused on the next frontier in cell therapy: solid tumors.
A2 engineers T cells that target the loss of genetic material in tumors, enabling the selective killing of tumor cells while leaving normal cells unharmed.
The company was founded in 2018 by Alexander Kamb, Michael Gallo and Paul Kang and has raised $136M since inception. Our investors include The Column Group, Vida Ventures, Samsara BioCapital, Nextech Invest, Casdin Capital, Euclidean Capital, UC Investments (Office of the Chief Investment Officer of the Regents) and Hartford HealthCare Endowment.
Company Details
- Employees
- 123
- Founded
- -
- Address
- 30301 Agoura Road,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- a2biotherapeutics.com
- Keywords
- Biotechnology, Immunotherapy, Oncology, Research, Target Identification, Cell Therapy, Manufacturing, Drug Development.
- HQ
- Agoura Hills, CA
A2 Biotherapeutics, Inc. Questions
A2 Biotherapeutics, Inc.'s website is a2biotherapeutics.com
A2 Biotherapeutics, Inc.'s LinkedIn profile is https://www.linkedin.com/company/a2-biotherapeutics
A2 Biotherapeutics, Inc. has
123 employees.
View email and phone details for 123
employees at A2 Biotherapeutics, Inc..
A2 Biotherapeutics, Inc.'s industry is
Biotechnology Research
A2 Biotherapeutics, Inc.'s top competitors are
Triveni Bio,
Avencell,
Seaport Therapeutics,
City Therapeutics,
Atalanta Therapeutics,
Kailera Therapeutics,
Aktis Oncology,
Aspect Biosystems,
Atbtherapeutics,
Terray Therapeutics.
A2 Biotherapeutics, Inc.'s categories are Biotechnology Research
A2 Biotherapeutics, Inc.'s founding year is 2018
